: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Flying Publisher

The Angels Initiative

Stroke prevention

Prostate Cancer

Free Subscription

Articles published in Prostate
Retrieve available abstracts of 321 articles:
HTML format

Single Articles

May 2023

SEMSARIAN CR, Ma T, Nickel B, Barratt A, et al
Low-risk prostate lesions: An evidence review to inform discussion on losing the "cancer" label.
Prostate. 2023;83:498-515.
PubMed Abstract available

WERNER RA, Habacha B, Lutje S, Bundschuh L, et al
Lack of repeatability of radiomic features derived from PET scans: Results from a (18) F-DCFPyL test-retest cohort.
Prostate. 2023;83:547-554.
PubMed Abstract available

April 2023

LU JG, Lo ET, Williams C, Ma B, et al
Expression of high molecular weight cytokeratin-A novel feature of aggressive and innate hormone-refractory prostatic adenocarcinoma.
Prostate. 2023;83:462-469.
PubMed Abstract available

March 2023

MAFFEI D, Fasulo V, Avolio PP, Saitta C, et al
Diagnostic performance of Micro-Ultrasound at MRI-guided confirmatory biopsy in patients under active surveillance for low-risk prostate cancer.
Prostate. 2023 Mar 24. doi: 10.1002/pros.24532.
PubMed Abstract available

STANGL-KREMSER J, Ricaurte-Fajardo A, Subramanian K, Osborne JR, et al
Response to RL-225Ac in prostate cancer: effect of prior treatment with RL-177Lu: a systematic review of the literature.
Prostate. 2023 Mar 24. doi: 10.1002/pros.24531.
PubMed Abstract available

OERTHER B, Engel H, Nedelcu A, Schlett CL, et al
Prediction of upgrade to clinically significant prostate cancer in patients under active surveillance: performance of a fully automated AI-algorithm for lesion detection and classification.
Prostate. 2023 Mar 23. doi: 10.1002/pros.24528.
PubMed Abstract available

CAPUTO SA, Hawkins M, Jaeger EB, Fleming W, et al
Clinical and Molecular Determinants of PSA Response to Bipolar Androgen Therapy in Prostate Cancer.
Prostate. 2023 Mar 23. doi: 10.1002/pros.24529.
PubMed Abstract available

HASAN S, Lazarev S, Garg M, Gozland R, et al
Proton therapy for high-risk prostate cancer: Results from the Proton Collaborative Group PCG 001-09 prospective registry trial.
Prostate. 2023 Mar 22. doi: 10.1002/pros.24525.
PubMed Abstract available

WONG CHM, Xu N, Lim J, Feng KK, et al
Adverse metabolic consequences of androgen deprivation therapy (ADT) on Asian patients with prostate cancer: Primary results from the real-life experience of ADT in Asia (READT) study.
Prostate. 2023 Mar 20. doi: 10.1002/pros.24519.
PubMed Abstract available

ROBECK P, Xu L, Ahmed D, Dragomir A, et al
P-score in preoperative biopsies accurately predicts P-score in final pathology at radical prostatectomy in patients with localized prostate cancer.
Prostate. 2023 Mar 20. doi: 10.1002/pros.24523.
PubMed Abstract available

LEWIS AR, Costello BA, Quevedo F, Pagliaro LC, et al
Dynamic assessment of serum chromogranin A and treatment response with abiraterone acetate in metastatic castration-resistant prostate cancer.
Prostate. 2023 Mar 16. doi: 10.1002/pros.24498.
PubMed Abstract available

TELLI T, Tuncel M, Karabulut E, Aksoy S, et al
Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with (177) Lu-PSMA-617. A single-center prospective observational study.
Prostate. 2023 Mar 15. doi: 10.1002/pros.24518.
PubMed Abstract available

CHIERIGO F, Flammia RS, Sorce G, Hoeh B, et al
The association of type and number of high-risk criteria with cancer specific mortality in prostate cancer patients treated with radiotherapy.
Prostate. 2023 Mar 15. doi: 10.1002/pros.24505.
PubMed Abstract available

TAN YG, Law YM, Ngo NT, Khor LY, et al
Patient-reported functional outcomes and oncological control after primary focal cryotherapy for clinically significant prostate cancer: A Phase II mandatory biopsy-monitored study.
Prostate. 2023 Mar 9. doi: 10.1002/pros.24517.
PubMed Abstract available

CHAMORRO CASTILLO L, Garcia Morales L, Ruiz Lopez D, Salguero Segura J, et al
The role of multiparametric magnetic resonance in active surveillance of a low-risk prostate cancer cohort from clinical practice.
Prostate. 2023 Mar 9. doi: 10.1002/pros.24515.
PubMed Abstract available

CONOVER MM, Weaver J, Fan B, Leitz G, et al
Cardiovascular outcomes among patients with castration-resistant prostate cancer: A comparative safety study using US administrative claims data.
Prostate. 2023 Mar 6. doi: 10.1002/pros.24510.
PubMed Abstract available

STINSON J, McCall C, Dobbs RW, Mistry N, et al
Vitamin D and genetic ancestry are associated with apoptosis rates in benign and malignant prostatic epithelium.
Prostate. 2023;83:352-363.
PubMed Abstract available

REN J, Melamed J, Taneja SS, Wysock JS, et al
Prostate magnetic resonance imaging-targeted biopsy global grade correlates better than highest grade with prostatectomy grade.
Prostate. 2023;83:323-330.
PubMed Abstract available

February 2023

BECK J, Rouleau M, Lemire F, Neveu B, et al
Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy.
Prostate. 2023 Feb 27. doi: 10.1002/pros.24501.
PubMed Abstract available

ZHUANG Q, Huang S, Li Z
Prospective role of 3betaHSD1 in prostate cancer precision medicine.
Prostate. 2023 Feb 26. doi: 10.1002/pros.24504.
PubMed Abstract available

OYENUGA M, Halabi S, Oyenuga A, McSweeney S, et al
Quality of life outcomes for patients with metastatic castration-resistant prostate cancer and pretreatment prognostic score.
Prostate. 2023 Feb 26. doi: 10.1002/pros.24503.
PubMed Abstract available

LEE J, Wickes BL, Fu J, Brockman NE, et al
Prevalence of genotoxic bacteria in men undergoing biopsy for prostate cancer.
Prostate. 2023 Feb 26. doi: 10.1002/pros.24500.
PubMed Abstract available

TIRUYE T, O'Callaghan M, Ettridge K, Jay A, et al
Factors impacting on sexual function among men on active surveillance for prostate cancer.
Prostate. 2023 Feb 24. doi: 10.1002/pros.24502.
PubMed Abstract available

ADAMS MN, Croft LV, Urquhart A, Saleem MAM, et al
hSSB1 (NABP2/OBFC2B) modulates the DNA damage and androgen-induced transcriptional response in prostate cancer.
Prostate. 2023 Feb 22. doi: 10.1002/pros.24496.
PubMed Abstract available

CHEN LC, Huang SP, Shih CT, Li CY, et al
ATP8B1: A prognostic prostate cancer biomarker identified via genetic analysis.
Prostate. 2023 Feb 15. doi: 10.1002/pros.24495.
PubMed Abstract available

GRAHAM LS, Haffner MC, Sayar E, Gawne A, et al
Clinical, pathologic, and molecular features of amphicrine prostate cancer.
Prostate. 2023 Feb 13. doi: 10.1002/pros.24497.
PubMed Abstract available

TAKESHITA N, Sakamoto S, Yamada Y, Sazuka T, et al
Detection of intraductal carcinoma in prostate cancer patients with small tumor volume.
Prostate. 2023 Feb 10. doi: 10.1002/pros.24492.
PubMed Abstract available

KARTHIKEYAN SK, Xu N, Ferguson Rd JE, Rais-Bahrami S, et al
Identification of androgen response-related lncRNAs in prostate cancer.
Prostate. 2023 Feb 9. doi: 10.1002/pros.24494.
PubMed Abstract available

January 2023

BRAY G, Bahadori A, Rama D
Salvage stereotactic body radiation therapy for locally recurrent prostate cancer following primary radiation therapy, are benefits worth toxicity risks?: A systematic review.
Prostate. 2023 Jan 30. doi: 10.1002/pros.24491.
PubMed Abstract available

RAM P, Mandal S, K Das M, Nayak P, et al
The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Prostate. 2023 Jan 30. doi: 10.1002/pros.24489.
PubMed

DIAMAND R, Peltier A, Roche JB, Lievore E, et al
Risk stratification for early biochemical recurrence of prostate cancer in the era of multiparametric magnetic resonance imagining-targeted biopsy.
Prostate. 2023 Jan 27. doi: 10.1002/pros.24490.
PubMed Abstract available

YANAGISAWA T, Hata K, Narita S, Hatakeyama S, et al
Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
Prostate. 2023 Jan 20. doi: 10.1002/pros.24488.
PubMed Abstract available

RAM P, Nayak P, Mandal S, Das MK, et al
Holmium laser enucleation of the prostate in men on active surveillance for prostate cancer with refractory lower urinary tract symptoms secondary to enlarged prostates.
Prostate. 2023 Jan 19. doi: 10.1002/pros.24487.
PubMed

DAVIDSSON S, Messing Eriksson A, Udumyan R, Swanholm P, et al
Androgen deprivation therapy in men with prostate cancer is not associated with COVID-2019 infection.
Prostate. 2023 Jan 19. doi: 10.1002/pros.24485.
PubMed Abstract available

STANGL A, Wilner C, Li P, Maahs L, et al
Molecular features and race-associated outcomes of SPOP-mutant metastatic castration-resistant prostate cancer.
Prostate. 2023 Jan 5. doi: 10.1002/pros.24481.
PubMed Abstract available

MAVURA Y, Song H, Xie J, Tamayo P, et al
Transcriptomic profiling and genomic rearrangement landscape of Nigerian prostate cancer.
Prostate. 2023 Jan 4. doi: 10.1002/pros.24471.
PubMed Abstract available

BHAT TA, Dheeraj A, Nambiar DK, Singh SP, et al
Decursin inhibits EGFR-ERK1/2 signaling axis in advanced human prostate carcinoma cells.
Prostate. 2023 Jan 3. doi: 10.1002/pros.24482.
PubMed Abstract available

AGUIAR JA, Li EV, Siddiqui MR, Soliman MA, et al
Utilization of genetic testing in men with advanced prostate cancer.
Prostate. 2023 Jan 2. doi: 10.1002/pros.24480.
PubMed Abstract available

BRODOWSKY EC, Sood A, Butaney M, Majdalany SE, et al
Time to second biochemical recurrence as a prognostic indicator in postprostatectomy patients who undergo salvage radiation therapy: An RTOG 9601 based post hoc analysis.
Prostate. 2023;83:64-70.
PubMed Abstract available

December 2022

CHANG T, Lian Z, Ma S, Liang Z, et al
Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH.
Prostate. 2022 Dec 28. doi: 10.1002/pros.24479.
PubMed Abstract available

WEI J, Beebe-Dimmer J, Shi Z, Sample C, et al
Association of rare, recurrent nonsynonymous variants in the germline of prostate cancer patients of African ancestry.
Prostate. 2022 Dec 25. doi: 10.1002/pros.24477.
PubMed Abstract available

RAJWA P, Pfister D, Rieger C, Heidenreich J, et al
Importance of magnetic resonance imaging and prostate-specific membrane antigen PET-CT in patients treated with salvage radical prostatectomy for radiorecurrent prostate cancer.
Prostate. 2022 Dec 23. doi: 10.1002/pros.24470.
PubMed Abstract available

FERNANDEZ-PEREZ MP, Perez-Navarro E, Alonso-Gordoa T, Conteduca V, et al
A correlative biomarker study and integrative prognostic model in chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide.
Prostate. 2022 Dec 23:e24469. doi: 10.1002/pros.24469.
PubMed Abstract available

UNTERBERGER CJ, McIlwain SJ, Tsourkas PK, Maklakova VI, et al
Conditional gene regulation models demonstrate a pro-proliferative role for growth hormone receptor in prostate cancer.
Prostate. 2022 Dec 22. doi: 10.1002/pros.24474.
PubMed Abstract available

ROSSETTO I, Santos F, Kido L, Lamas C, et al
Tempol differential effect on prostate cancer inflammation: In vitro and in vivo evaluation.
Prostate. 2022 Dec 22. doi: 10.1002/pros.24473.
PubMed Abstract available

YANG J, Tang Y, Zhou C, Zhou M, et al
The use of (68) Ga-PSMA PET/CT to stratify patients with PI-RADS 3 lesions according to clinically significant prostate cancer risk.
Prostate. 2022 Dec 21. doi: 10.1002/pros.24475.
PubMed Abstract available

XU Y, Xu M, Li X, Weng X, et al
SOX9 and HMGB3 co-operatively transactivate NANOG and promote prostate cancer progression.
Prostate. 2022 Dec 21. doi: 10.1002/pros.24476.
PubMed Abstract available

JURACEK J, Madrzyk M, Stanik M, Ruckova M, et al
A tissue miRNA expression pattern is associated with disease aggressiveness of localized prostate cancer.
Prostate. 2022 Dec 8. doi: 10.1002/pros.24466.
PubMed Abstract available

SASAKI T, Yoshikawa Y, Kageyama T, Sugino Y, et al
Prostate fibroblasts enhance androgen receptor splice variant 7 expression in prostate cancer cells.
Prostate. 2022 Dec 7. doi: 10.1002/pros.24468.
PubMed Abstract available

KAZAN O, Gunduz N, Kir G, Iplikci A, et al
The cribriform morphology impairs Gleason 7 prostate cancer lesion detection on multiparametric magnetic resonance imaging.
Prostate. 2022 Dec 7. doi: 10.1002/pros.24465.
PubMed Abstract available

AMARO GM, da Silva ADT, Tamarindo GH, Lamas CA, et al
Differential effects of omega-3 PUFAS on tumor progression at early and advanced stages in TRAMP mice.
Prostate. 2022;82:1491-1504.
PubMed Abstract available

DENMEADE S, Lim SJ, Isaaccson Velho P, Wang H, et al
PSA provocation by bipolar androgen therapy may predict duration of response to first-line androgen deprivation: Updated results from the BATMAN study.
Prostate. 2022;82:1529-1536.
PubMed Abstract available

November 2022

MIYAHIRA AK, Hawley JE, Adelaiye-Ogala R, Calais J, et al
Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey-Holden prostate cancer academy meeting.
Prostate. 2022 Nov 28. doi: 10.1002/pros.24461.
PubMed Abstract available

NAITO Y, Kato M, Kawanishi H, Yamamoto A, et al
Clinical utility of intraductal carcinoma of the prostate in treatment selection for metastatic hormone-sensitive prostate cancer.
Prostate. 2022 Nov 24. doi: 10.1002/pros.24462.
PubMed Abstract available

SU CT, Nizialek E, Berchuck JE, Vlachostergios PJ, et al
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
Prostate. 2022 Nov 16. doi: 10.1002/pros.24454.
PubMed Abstract available

ALASKAR A, Abdulraqeb Ali A, Hassan S, Shinwari Z, et al
Inhibition of signaling downstream of beta-2 adrenoceptor by propranolol in prostate cancer cells.
Prostate. 2022 Nov 14. doi: 10.1002/pros.24455.
PubMed Abstract available

TRABZONLU L, Pienta KJ, Trock BJ, De Marzo AM, et al
Presence of cells in the polyaneuploid cancer cell (PACC) state predicts the risk of recurrence in prostate cancer.
Prostate. 2022 Nov 13. doi: 10.1002/pros.24459.
PubMed Abstract available

PANUNZIO A, Sorce G, Hoeh B, Hohenhorst L, et al
Effect of positive surgical margins at radical prostatectomy on cancer-specific mortality in high/very high-risk prostate cancer patients with Gleason Grade Group 4-5.
Prostate. 2022 Nov 6. doi: 10.1002/pros.24458.
PubMed Abstract available

NYGARD LH, Talala K, Taari K, Tammela TLJ, et al
Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia.
Prostate. 2022 Nov 3. doi: 10.1002/pros.24456.
PubMed Abstract available

CHAN JSK, Tang P, Hui JMH, Lee YHA, et al
Association between duration of gonadotrophin-releasing hormone agonist use and cardiovascular risks: A population-based competing-risk analysis.
Prostate. 2022;82:1477-1480.
PubMed Abstract available

BROWN NE, Jones A, Hunt BG, Waltz SE, et al
Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6-mediated Axl and RON signaling.
Prostate. 2022;82:1422-1437.
PubMed Abstract available

October 2022

LEE EE, Singh T, Hu C, Han M, et al
The impact of salvage radiotherapy initiation at PSA
Prostate. 2022 Oct 31. doi: 10.1002/pros.24452.
PubMed Abstract available

OISHI T, Hatakeyama S, Tabata R, Fujimori D, et al
Effects of apalutamide dose reduction on skin-related adverse events in patients with advanced prostate cancer: A multicenter retrospective study.
Prostate. 2022 Oct 31. doi: 10.1002/pros.24453.
PubMed Abstract available

NIU S, Liu Y, Ding X, Xu Y, et al
(18) F-DCFPyL positron emission tomography/magnetic resonance imaging-guided ultrasound fusion biopsy is an identical pathway in prostate cancer diagnosis.
Prostate. 2022 Oct 25. doi: 10.1002/pros.24446.
PubMed Abstract available

ODERDA M, Albisinni S, Benamran D, Calleris G, et al
Accuracy of elastic fusion biopsy: Comparing prostate cancer detection between targeted and systematic biopsy.
Prostate. 2022 Oct 19. doi: 10.1002/pros.24449.
PubMed Abstract available

SATAPATHY S, Das CK, Aggarwal P, Sood A, et al
Genomic characterization of metastatic castration-resistant prostate cancer patients undergoing PSMA radioligand therapy: A single-center experience.
Prostate. 2022 Oct 19. doi: 10.1002/pros.24450.
PubMed Abstract available

CHENG S, Yu X
CTPC, a combined transcriptome data set of human prostate cancer cell lines.
Prostate. 2022 Oct 7. doi: 10.1002/pros.24448.
PubMed Abstract available

HARPER JB, Greenberg SE, Hunt TC, Cooney KA, et al
Initial outcomes and insights from a novel high-risk prostate cancer screening clinic.
Prostate. 2022 Oct 7. doi: 10.1002/pros.24447.
PubMed Abstract available

OU W, Lei J, Li M, Zhang X, et al
Ultrasound-based radiomics score for pre-biopsy prediction of prostate cancer to reduce unnecessary biopsies.
Prostate. 2022 Oct 7. doi: 10.1002/pros.24442.
PubMed Abstract available

HARTRAMPF PE, Weinzierl FX, Seitz AK, Kubler H, et al
Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy.
Prostate. 2022;82:1406-1412.
PubMed Abstract available

VERMA S, Kushwaha PP, Shankar E, Ponsky LE, et al
Increased cytokine gene expression and cognition risk associated with androgen deprivation therapy.
Prostate. 2022;82:1389-1399.
PubMed Abstract available

WONG WW, Hillman DW, Daniels TB, Vargas CE, et al
A Phase II prospective study of hypofractionated proton therapy of prostate and pelvic lymph nodes: Acute effects on patient-reported quality of life.
Prostate. 2022;82:1338-1345.
PubMed Abstract available

September 2022

LEE YHA, Hui JMH, Chan JSK, Liu K, et al
Metformin use and mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: A population-based study.
Prostate. 2022 Sep 30. doi: 10.1002/pros.24443.
PubMed Abstract available

MUSTAFFA A, Emara S
Safely omitting bone isotope scans in a cohort of grade group 2 prostate cancer.
Prostate. 2022 Sep 29. doi: 10.1002/pros.24444.
PubMed Abstract available

URABE F, Miki K, Kimura T, Sasaki H, et al
Long-term outcomes of radical prostatectomy versus low-dose-rate brachytherapy in patients with intermediate-risk prostate cancer: Propensity score matched comparison.
Prostate. 2022 Sep 29. doi: 10.1002/pros.24445.
PubMed Abstract available

WANG S, Zhang C, Xu Z, Chen MH, et al
Differential impact of PI3K/AKT/mTOR signaling on tumor initiation and progression in animal models of prostate cancer.
Prostate. 2022 Sep 26. doi: 10.1002/pros.24441.
PubMed Abstract available

ALAMIRI J, Britton CJ, Ahmed ME, Andrews JR, et al
Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis.
Prostate. 2022 Sep 11. doi: 10.1002/pros.24413.
PubMed Abstract available

SCHMID FA, Lieger L, Saba K, Sigg S, et al
Therapy decisions after diagnosis of prostate cancer in men with negative prostate MRI.
Prostate. 2022 Sep 8. doi: 10.1002/pros.24435.
PubMed Abstract available

LIN R, Yang Y, Wu E, Zhou M, et al
SIRT2 promotes cell proliferation and migration through mediating ERK1/2 activation and lactosylceramide accumulation in prostate cancer.
Prostate. 2022 Sep 8. doi: 10.1002/pros.24437.
PubMed Abstract available

SCHOBER JP, Stensland KD, Moinzadeh A, Canes D, et al
Holmium laser enucleation of the prostate in men on active surveillance for prostate cancer with refractory lower urinary tract symptoms secondary to enlarged prostates.
Prostate. 2022 Sep 5. doi: 10.1002/pros.24433.
PubMed Abstract available

KC M, Oral E, Rung AL, Trapido E, et al
Prostate cancer aggressiveness and financial toxicity among prostate cancer patients.
Prostate. 2022 Sep 5. doi: 10.1002/pros.24434.
PubMed Abstract available

August 2022

SEMIZ HS, Kucuk U, Kisa E, Keskinkilic M, et al
CD47 (don't eat me signal) expression levels and its relationship with clinicopathologic features in early-stage prostate carcinoma.
Prostate. 2022 Aug 28. doi: 10.1002/pros.24432.
PubMed Abstract available

RUAN X, Huang D, Huang J, Xu D, et al
Application of European-specific polygenic risk scores for predicting prostate cancer risk in different ancestry populations.
Prostate. 2022 Aug 22. doi: 10.1002/pros.24431.
PubMed Abstract available

KARELIA DN, Kim S, Plano D, Sharma AK, et al
Seleno-aspirin compound AS-10 promotes histone acetylation ahead of suppressing androgen receptor transcription, G1 arrest, and apoptosis of prostate cancer cells.
Prostate. 2022 Aug 22. doi: 10.1002/pros.24430.
PubMed Abstract available

DYMANUS K, Howard LE, Oyekunle T, De Hoedt AM, et al
Are higher pre-diagnosis follicle stimulating hormone levels associated with long-term prostate cancer risk?
Prostate. 2022 Aug 18. doi: 10.1002/pros.24429.
PubMed Abstract available

FILON MJ, Gillette AA, Yang B, Khemees TA, et al
Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy.
Prostate. 2022 Aug 18. doi: 10.1002/pros.24428.
PubMed Abstract available

MAYNARD JP, Godwin TN, Lu J, Vidal I, et al
Localization of macrophage subtypes and neutrophils in the prostate tumor microenvironment and their association with prostate cancer racial disparities.
Prostate. 2022 Aug 16. doi: 10.1002/pros.24424.
PubMed Abstract available

TAKAMORI H, Urabe F, Matsuzaki J, Kimura S, et al
Circulating microRNA profiling for prediction of oncological outcomes in prostate cancer patients following radical prostatectomy.
Prostate. 2022 Aug 16. doi: 10.1002/pros.24427.
PubMed Abstract available

TERRACCIANO D, La Civita E, Athanasiou A, Liotti A, et al
New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index.
Prostate. 2022 Aug 16. doi: 10.1002/pros.24422.
PubMed Abstract available

WANG S, Ryan Russell J, Drescher M, Park A, et al
Prostate cancer grade downgrading at time of prostatectomy provides risk-stratification insight into future tumor behavior after prostatectomy.
Prostate. 2022 Aug 3. doi: 10.1002/pros.24425.
PubMed Abstract available

LOMBARDO R, Rovesti L, Cicione A, Gravina C, et al
Serum levels of chromogranin are not predictive of poorly differentiated prostate cancer: Results from a multicenter radical prostatectomy cohort.
Prostate. 2022 Aug 3. doi: 10.1002/pros.24412.
PubMed Abstract available

KWAN EM, Wyatt AW
Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer.
Prostate. 2022;82 Suppl 1:S25-S36.
PubMed Abstract available

SUTERA P, Deek MP, Van der Eecken K, Wyatt AW, et al
Genomic biomarkers to guide precision radiotherapy in prostate cancer.
Prostate. 2022;82 Suppl 1:S73-S85.
PubMed Abstract available

KHAN HM, Cheng HH
Germline genetics of prostate cancer.
Prostate. 2022;82 Suppl 1:S3-S12.
PubMed Abstract available

CRESTA MORGADO P, Mateo J
Clinical implications of homologous recombination repair mutations in prostate cancer.
Prostate. 2022;82 Suppl 1:S45-S59.
PubMed Abstract available

COTTER K, Rubin MA
The evolving landscape of prostate cancer somatic mutations.
Prostate. 2022;82 Suppl 1:S13-S24.
PubMed Abstract available

ANTONARAKIS ES
Genetics and genomics of prostate cancer and therapeutic implications.
Prostate. 2022;82 Suppl 1:S1-S2.
PubMed

MIZUNO K, Beltran H
Future directions for precision oncology in prostate cancer.
Prostate. 2022;82 Suppl 1:S86-S96.
PubMed Abstract available

CHOUDHURY AD
PTEN-PI3K pathway alterations in advanced prostate cancer and clinical implications.
Prostate. 2022;82 Suppl 1:S60-S72.
PubMed Abstract available

LI G, Xia YF, Huang YX, Okat D, et al
Better preservation of erectile function in localized prostate cancer patients with modern proton therapy: Is it cost-effective?
Prostate. 2022 Aug 1. doi: 10.1002/pros.24417.
PubMed Abstract available

UCAR T, Gunduz N, Demirci E, Culpan M, et al
Comparison of 68Ga-PSMA PET/CT and mp-MRI in regard to local staging for prostate cancer with histopathological results: A retrospective study.
Prostate. 2022 Aug 1. doi: 10.1002/pros.24420.
PubMed Abstract available

July 2022

YAZGAN SC, Yekeduz E, Utkan G, Urun Y, et al
Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors.
Prostate. 2022 Jul 28. doi: 10.1002/pros.24419.
PubMed Abstract available

KHAN S, Vohra S, Farnan L, Elmore SNC, et al
Using health insurance claims data to assess long-term disease progression in a prostate cancer cohort.
Prostate. 2022 Jul 26. doi: 10.1002/pros.24418.
PubMed Abstract available

WANG Y, Tang Y, Gao X, Gan Y, et al
Optimization of prostate cancer patient lymph node staging via the integration of neutrophil-lymphocyte ratios, platelet-lymphocyte ratios, and (68) Ga-PSMA-PET-derived SUVmax values.
Prostate. 2022 Jul 21. doi: 10.1002/pros.24415.
PubMed Abstract available

MIYAHIRA AK, Soule HR
The 28th Annual Prostate Cancer Foundation Scientific Retreat report.
Prostate. 2022 Jul 18. doi: 10.1002/pros.24409.
PubMed Abstract available

MODONUTTI D, Majdalany SE, Corsi N, Li P, et al
A novel prognostic model predicting overall survival in patients with metastatic castration-resistant prostate cancer receiving standard chemotherapy: A multi-trial cohort analysis.
Prostate. 2022 Jul 5. doi: 10.1002/pros.24403.
PubMed Abstract available

RAMIREZ-TORRES A, Reagan AL, Howard LE, Wiggins E, et al
Racial differences in circulating mitochondria-derived peptides may contribute to prostate cancer health disparities.
Prostate. 2022 Jul 5. doi: 10.1002/pros.24398.
PubMed Abstract available

June 2022

YANAGISAWA T, Kimura T, Hata K, Narita S, et al
Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.
Prostate. 2022 Jun 29. doi: 10.1002/pros.24406.
PubMed Abstract available

CASADO-LLOMBART S, Ajami T, Consuegra-Fernandez M, Carreras E, et al
Gene variation impact on prostate cancer progression: Lymphocyte modulator, activation, and cell adhesion gene variant contribution.
Prostate. 2022 Jun 29. doi: 10.1002/pros.24407.
PubMed Abstract available

BRAY AW, Duan R, Malalur P, Drusbosky LM, et al
Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer.
Prostate. 2022 Jun 29. doi: 10.1002/pros.24400.
PubMed Abstract available

MIURA Y, Hatakeyama S, Narita S, Kimura T, et al
Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
Prostate. 2022 Jun 23. doi: 10.1002/pros.24404.
PubMed Abstract available

YANG T, Liu Y, Chen S, Tian J, et al
Serum prolactin level as a predictive factor for abiraterone response in patients with metastatic castration-resistant prostate cancer.
Prostate. 2022 Jun 23. doi: 10.1002/pros.24402.
PubMed Abstract available

HEARD JR, Huang AJ, Werle L, Adler K, et al
Definitive treatment choice among Black immigrants with prostate cancer: Analysis of patient surveys distributed at a single safety-net institution.
Prostate. 2022 Jun 23. doi: 10.1002/pros.24399.
PubMed Abstract available

STENZL A, Szmulewitz RZ, Petrylak D, Holzbeierlein J, et al
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
Prostate. 2022 Jun 8. doi: 10.1002/pros.24396.
PubMed Abstract available

LIU AJ, Kosiorek HE, Ueberroth BE, Jaeger E, et al
The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Prostate. 2022 Jun 2. doi: 10.1002/pros.24375.
PubMed Abstract available

SORCE G, Hoeh B, Flammia RS, Chierigo F, et al
Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level.
Prostate. 2022 Jun 2. doi: 10.1002/pros.24376.
PubMed Abstract available

CHO HL, Murthy V, Mouw KW, D'Amico AV, et al
Second malignancy probabilities in patients with prostate cancer treated with whole pelvis radiation therapy versus prostate only radiation therapy.
Prostate. 2022 Jun 2. doi: 10.1002/pros.24362.
PubMed Abstract available

ABDI B, Basset N, Perrot E, Benderra MA, et al
DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries.
Prostate. 2022 Jun 2. doi: 10.1002/pros.24374.
PubMed Abstract available

MUNOZ-MORENO L, Carmena MJ, Prieto JC, Schally AV, et al
Tumorigenic transformation of human prostatic epithelial cell line RWPE-1 by growth hormone-releasing hormone (GHRH).
Prostate. 2022;82:933-941.
PubMed Abstract available

FUJIWARA M, Numao N, Yamamoto S, Ishikawa Y, et al
Predictive ability of prebiopsy magnetic resonance imaging and biopsy for side-specific negative lymph node metastasis at radical prostatectomy.
Prostate. 2022;82:904-910.
PubMed Abstract available

HOLZE S, Lemaire E, Mende M, Neuhaus P, et al
Quality of life after robotic-assisted and laparoscopic radical prostatectomy: Results of a multicenter randomized controlled trial (LAP-01).
Prostate. 2022;82:894-903.
PubMed Abstract available

RATNANI P, Dovey Z, Parekh S, Sobotka S, et al
Prostate MRI percentage tumor involvement or "PI-RADS percent" as a predictor of adverse surgical pathology.
Prostate. 2022;82:970-983.
PubMed Abstract available

May 2022

ASKER H, Yilmaz-Oral D, Oztekin CV, Gur S, et al
An update on the current status and future prospects of erectile dysfunction following radical prostatectomy.
Prostate. 2022 May 17. doi: 10.1002/pros.24366.
PubMed Abstract available

PELLEGRINO F, Stabile A, Mazzone E, Sorce G, et al
Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series.
Prostate. 2022 May 10. doi: 10.1002/pros.24368.
PubMed Abstract available

HE Y, Shen Q, Fu W, Wang H, et al
Optimized grade group for reporting prostate cancer grade in systematic and MRI-targeted biopsies.
Prostate. 2022 May 10. doi: 10.1002/pros.24365.
PubMed Abstract available

MORGANS AK, Chen YH, Jarrard DF, Carducci M, et al
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805.
Prostate. 2022 May 10. doi: 10.1002/pros.24369.
PubMed Abstract available

SAKELLAKIS M
Orphan receptors in prostate cancer.
Prostate. 2022 May 10. doi: 10.1002/pros.24370.
PubMed Abstract available

KEEGAN NM, Vasselman SE, Barnett ES, Nweji B, et al
Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality.
Prostate. 2022 May 10. doi: 10.1002/pros.24363.
PubMed Abstract available

DENMEADE S, Antonarakis ES, Markowski MC
Bipolar androgen therapy (BAT): A patient's guide.
Prostate. 2022;82:753-762.
PubMed Abstract available

VITEK RA, Huang W, Geiger PG, Heninger E, et al
Fresh tissue procurement and preparation for multicompartment and multimodal analysis of the prostate tumor microenvironment.
Prostate. 2022;82:836-849.
PubMed Abstract available

LUNACEK A, Tischler M, Mrstik C, Hebenstreit D, et al
Effects of cycling and rowing on serum concentrations of prostate-specific antigen: A randomized study of 101 male subjects.
Prostate. 2022;82:804-808.
PubMed Abstract available

April 2022

BOSLAND MC, Horton L, Condon MS
Effects of green tea on prostate carcinogenesis in rat models and a human prostate cancer xenograft model.
Prostate. 2022 Apr 29. doi: 10.1002/pros.24364.
PubMed Abstract available

WITHROW D, Pilleron S, Nikita N, Ferlay J, et al
Current and projected number of years of life lost due to prostate cancer: A global study.
Prostate. 2022 Apr 25. doi: 10.1002/pros.24360.
PubMed Abstract available

WANG M, Qi J, George AK, Semerjian A, et al
The added influence of genomics and post-MRI confirmatory biopsy results to MRI results alone on medical decision making for men with favorable risk prostate cancer being considered for active surveillance.
Prostate. 2022 Apr 25. doi: 10.1002/pros.24357.
PubMed Abstract available

HU Q, Hong X, Xu L, Jia R, et al
A nomogram for accurately predicting the pathological upgrading of prostate cancer, based on (68) Ga-PSMA PET/CT.
Prostate. 2022 Apr 25. doi: 10.1002/pros.24358.
PubMed Abstract available

YUEN KC, Tran B, Anton A, Hamidi H, et al
Molecular classification of hormone-sensitive and castration-resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens.
Prostate. 2022 Apr 18. doi: 10.1002/pros.24346.
PubMed Abstract available

PITAK-ARNNOP P, Messer-Peti R, Tangmanee C, Neff A, et al
Prostate cancer awareness among transgender women after gender-affirming surgery.
Prostate. 2022 Apr 13. doi: 10.1002/pros.24355.
PubMed Abstract available

MORI JO, Shafran JS, Stojanova M, Katz MH, et al
Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins.
Prostate. 2022 Apr 11. doi: 10.1002/pros.24351.
PubMed Abstract available

FLAMMIA RS, Hoeh B, Sorce G, Chierigo F, et al
Contemporary seminal vesicle invasion rates in NCCN high-risk prostate cancer patients.
Prostate. 2022 Apr 11. doi: 10.1002/pros.24350.
PubMed Abstract available

LV X, Li Y, Li R, Guan X, et al
Relationships of sleep traits with prostate cancer risk: A prospective study of 213,999 UK Biobank participants.
Prostate. 2022 Apr 11. doi: 10.1002/pros.24345.
PubMed Abstract available

SORCE G, Flammia RS, Hoeh B, Chierigo F, et al
Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates.
Prostate. 2022 Apr 1. doi: 10.1002/pros.24349.
PubMed Abstract available

YAMAGUCHI M, Murata T, Ramos JW
Overexpression of regucalcin blocks the migration, invasion, and bone metastatic activity of human prostate cancer cells: Crosstalk between cancer cells and bone cells.
Prostate. 2022 Apr 1. doi: 10.1002/pros.24348.
PubMed Abstract available

ZHOU Z, Liang Z, Zuo Y, Zhou Y, et al
Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
Prostate. 2022;82:556-565.
PubMed Abstract available

CHEN Z, Wu J, Sun K, He Y, et al
Risk model based on MRI fusion biopsy characteristics predicts biochemical recurrence after radical prostatectomy.
Prostate. 2022;82:566-575.
PubMed Abstract available

LINDH C, Samaratunga H, Delahunt B, Bergstrom R, et al
Ductal and acinar components of mixed prostatic adenocarcinoma frequently have a common clonal origin.
Prostate. 2022;82:576-583.
PubMed Abstract available

WEI X, Roudier MP, Kwon OJ, Lee JD, et al
Paracrine Wnt signaling is necessary for prostate epithelial proliferation.
Prostate. 2022;82:517-530.
PubMed Abstract available

March 2022

GRAHAM LS, Schweizer MT
Mismatch repair deficiency and clinical implications in prostate cancer.
Prostate. 2022 Mar 31. doi: 10.1002/pros.24343.
PubMed Abstract available

PREISSER F, Heinze A, S Abrams-Pompe R, Budaus L, et al
Impact of positive surgical margin length and Gleason grade at the margin on oncologic outcomes in patients with nonorgan-confined prostate cancer.
Prostate. 2022 Mar 28. doi: 10.1002/pros.24341.
PubMed Abstract available

SINGH CK, Denu RA, Nihal M, Shabbir M, et al
PLK4 is upregulated in prostate cancer and its inhibition reduces centrosome amplification and causes senescence.
Prostate. 2022 Mar 25. doi: 10.1002/pros.24342.
PubMed Abstract available

MAO F, Kong Y, Liu J, Rao X, et al
Diptoindonesin G antagonizes AR signaling and enhances the efficacy of antiandrogen therapy in prostate cancer.
Prostate. 2022 Mar 24. doi: 10.1002/pros.24336.
PubMed Abstract available

LUNDGREN PO, Tribukait B, Kjellman A, Norming U, et al
Serum thymidine kinase 1 concentration as a predictive biomarker in prostate cancer.
Prostate. 2022 Mar 16. doi: 10.1002/pros.24335.
PubMed Abstract available

SADAGHIANI MS, Sheikhbahaei S, Werner RA, Pienta KJ, et al
(177) Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: An updated systematic review and meta-analysis.
Prostate. 2022 Mar 14. doi: 10.1002/pros.24325.
PubMed Abstract available

ZHANG T, Kephart J, Bronson E, Anand M, et al
Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer.
Prostate. 2022 Mar 14. doi: 10.1002/pros.24329.
PubMed Abstract available

ANTONARAKIS ES, Tierno M, Fisher V, Tukachinsky H, et al
Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer.
Prostate. 2022 Mar 14. doi: 10.1002/pros.24331.
PubMed Abstract available

SENTANA-LLEDO D, Sartor O, Balk SP, Einstein DJ, et al
Immune mechanisms behind prostate cancer in men of African ancestry: A review.
Prostate. 2022 Mar 7. doi: 10.1002/pros.24333.
PubMed Abstract available

BECKMANN KR, Bangma CH, Helleman J, Bjartell A, et al
Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database.
Prostate. 2022 Mar 7. doi: 10.1002/pros.24330.
PubMed Abstract available

HINOJOSA-GONZALEZ DE, Roblesgil-Medrano A, Torres-Martinez M, Alanis-Garza C, et al
Single-port versus multiport robotic-assisted radical prostatectomy: A systematic review and meta-analysis on the da Vinci SP platform.
Prostate. 2022;82:405-414.
PubMed Abstract available

LEITSMANN C, Uhlig A, Bremmer F, Mut TT, et al
Impact of mpMRI targeted biopsy on intraoperative nerve-sparing (NeuroSAFE) during robot-assisted laparoscopic radical prostatectomy.
Prostate. 2022;82:493-501.
PubMed Abstract available

KOPARAL MY, Sozen TS, Karsiyakali N, Aslan G, et al
Comparison of transperineal and transrectal targeted prostate biopsy using Mahalanobis distance matching within propensity score caliper method: A multicenter study of Turkish Urooncology Association.
Prostate. 2022;82:425-432.
PubMed Abstract available

February 2022

CHIERIGO F, Borghesi M, Wurnschimmel C, Flammia RS, et al
Survival after radical prostatectomy versus radiation therapy in clinical node-positive prostate cancer.
Prostate. 2022 Feb 28. doi: 10.1002/pros.24317.
PubMed Abstract available

PURAYIL HT, Daaka Y
betaArrestin1 regulates glucocorticoid receptor mitogenic signaling in castration-resistant prostate cancer.
Prostate. 2022 Feb 28. doi: 10.1002/pros.24324.
PubMed Abstract available

LIU JM, Chen YT, Wu CT, Hsu WL, et al
Androgen deprivation therapy for prostate cancer and the risk of thyroid diseases.
Prostate. 2022 Feb 28. doi: 10.1002/pros.24323.
PubMed Abstract available

K C M, Oral E, Rung AL, Trapido EJ, et al
Neighborhood deprivation and risk of mortality among men with prostate cancer: Findings from a long-term follow-up study.
Prostate. 2022 Feb 24. doi: 10.1002/pros.24320.
PubMed Abstract available

KANEKO M, Fukuda N, Nagano H, Yamada K, et al
Artificial intelligence trained with integration of multiparametric MR-US imaging data and fusion biopsy trajectory-proven pathology data for 3D prediction of prostate cancer: A proof-of-concept study.
Prostate. 2022 Feb 22. doi: 10.1002/pros.24321.
PubMed Abstract available

IZOL V, Ok F, Aslan G, Akdogan B, et al
Effect of pelvic lymph node dissection and its extent on oncological outcomes in intermediate-risk prostate cancer patients: A multicenter study of the Turkish Uro-oncology Association.
Prostate. 2022 Feb 21. doi: 10.1002/pros.24318.
PubMed Abstract available

OZBEK B, Ertunc O, Erickson A, Vidal ID, et al
Multiplex immunohistochemical phenotyping of T cells in primary prostate cancer.
Prostate. 2022 Feb 21. doi: 10.1002/pros.24315.
PubMed Abstract available

HOEH B, Flammia RS, Hohenhorst L, Sorce G, et al
Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients.
Prostate. 2022 Feb 21. doi: 10.1002/pros.24313.
PubMed Abstract available

HOEH B, Wurnschimmel C, Flammia RS, Horlemann B, et al
Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups.
Prostate. 2022 Feb 21. doi: 10.1002/pros.24312.
PubMed Abstract available

PAGEL CN, Kularathna PK, Sanaei R, Young ND, et al
Protease-activated receptor-2 dependent and independent responses of bone cells to prostate cancer cell secretory products.
Prostate. 2022 Feb 15. doi: 10.1002/pros.24316.
PubMed Abstract available

WANG Y, Abenojar EC, Wang J, de Leon AC, et al
Development of a novel castration-resistant orthotopic prostate cancer model in New Zealand White rabbit.
Prostate. 2022 Feb 15. doi: 10.1002/pros.24314.
PubMed Abstract available

STAMIS SA, Heath EI, Lucas S, Boerner J, et al
Alcohol dehydrogenase expression patterns in normal prostate, benign prostatic hyperplasia, and prostatic adenocarcinoma in African American and Caucasian men.
Prostate. 2022 Feb 8. doi: 10.1002/pros.24310.
PubMed Abstract available

SUN Y, Ai JZ, Jin X, Liu LR, et al
IL-8 protects prostate cancer cells from GSK-3beta-induced oxidative stress by activating the mTOR signaling pathway.
Prostate. 2022;82:401-402.
PubMed

URAKAMI A, Arimura H, Takayama Y, Kinoshita F, et al
Stratification of prostate cancer patients into low- and high-grade groups using multiparametric magnetic resonance radiomics with dynamic contrast-enhanced image joint histograms.
Prostate. 2022;82:330-344.
PubMed Abstract available

WENZEL M, Colla Ruvolo C, Wurnschimmel C, Nocera L, et al
Response to the letter to the editor: "Don't throw the baby out with the bath water" by Horsley et al.
Prostate. 2022;82:399-400.
PubMed

HORSLEY PJ, Kneebone A, Eade TN, Hruby G, et al
Don't throw the baby out with the bath water.
Prostate. 2022;82:397-398.
PubMed

MA C, Downes M, Jain R, Ientilucci M, et al
Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with syn- or metachronous metastatic disease.
Prostate. 2022;82:345-351.
PubMed Abstract available

ZENNER ML, Helou YB, Deaton RJ, Sverdlov M, et al
Advanced glycation end-products (AGEs) are lower in prostate tumor tissue and inversely related to proportion of West African ancestry.
Prostate. 2022;82:306-313.
PubMed Abstract available

ARCOT R, Cher ML, Qi J, Linsell SM, et al
Delayed radical prostatectomy after a period of active surveillance is not associated with the use of secondary treatments compared with immediate prostatectomy.
Prostate. 2022;82:323-329.
PubMed Abstract available

TAN YG, Fang AHS, Lim JKS, Khalid F, et al
Incorporating artificial intelligence in urology: Supervised machine learning algorithms demonstrate comparative advantage over nomograms in predicting biochemical recurrence after prostatectomy.
Prostate. 2022;82:298-305.
PubMed Abstract available

MA H, Xu W, Ni J, Zhao N, et al
Phase I clinical trial of HC-1119 soft capsule in Chinese healthy adult male subjects: Pharmacokinetics and safety of single-dose proportionality and effects of food.
Prostate. 2022;82:276-285.
PubMed Abstract available

LI N, Song WJ, Gao J, Xu ZP, et al
The prognostic nutritional index predicts the biochemical recurrence of patients treated with robot-assisted laparoscopic radical prostatectomy.
Prostate. 2022;82:221-226.
PubMed Abstract available

AUSSAVAVIROJEKUL P, Hoonlor A, Srinualnad S
Optimization of clinical risk-factor interpretation and radiological findings with machine learning for PIRADS category 3 patients.
Prostate. 2022;82:235-244.
PubMed Abstract available

SIEDOW M, Eisner M, Yaney A, Washington I, et al
Impact of prostate biopsy secondary pathology review on radiotherapy management.
Prostate. 2022;82:210-215.
PubMed Abstract available

January 2022

LUNA VELEZ MV, Paulino da Silva Filho O, Verhaegh GW, van Hooij O, et al
Delivery of antisense oligonucleotides for splice-correction of androgen receptor pre-mRNA in castration-resistant prostate cancer models using cell-penetrating peptides.
Prostate. 2022 Jan 31. doi: 10.1002/pros.24309.
PubMed Abstract available

GARCIA-MARQUES F, Liu S, Totten SM, Bermudez A, et al
Protein signatures to distinguish aggressive from indolent prostate cancer.
Prostate. 2022 Jan 31. doi: 10.1002/pros.24307.
PubMed Abstract available

ZHAO R, Lv Y, Feng T, Zhang R, et al
ATF6alpha promotes prostate cancer progression by enhancing PLA2G4A-mediated arachidonic acid metabolism and protecting tumor cells against ferroptosis.
Prostate. 2022 Jan 28. doi: 10.1002/pros.24308.
PubMed Abstract available

STOVER EH, Oh C, Keskula P, Choudhury AD, et al
Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples.
Prostate. 2022 Jan 27. doi: 10.1002/pros.24305.
PubMed Abstract available

MOLL JM, Hofland J, Teubel WJ, de Ridder CMA, et al
Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
Prostate. 2022 Jan 17. doi: 10.1002/pros.24297.
PubMed Abstract available

ZHU S, Zhang Z, Zhang H, Liu Z, et al
DNA-repair status should be assessed in treatment-emergent neuroendocrine prostate cancer before platinum-based therapy.
Prostate. 2022 Jan 17. doi: 10.1002/pros.24292.
PubMed Abstract available

ZHOU J, Chen H, Wu Y, Shi B, et al
Plasma IL-6 and TNF-alpha levels correlate significantly with grading changes in localized prostate cancer.
Prostate. 2022 Jan 17. doi: 10.1002/pros.24299.
PubMed Abstract available

CAO Y, Song DY, Deville C, DeWeese TL, et al
Radiating the prostate bed in relapsed oligometastatic prostate cancer: How comprehensive should we be?
Prostate. 2022 Jan 11. doi: 10.1002/pros.24301.
PubMed Abstract available

RASPIN K, O'Malley DE, Marthick JR, Donovan S, et al
Analysis of a large prostate cancer family identifies novel and recurrent gene fusion events providing evidence for inherited predisposition.
Prostate. 2022 Jan 7. doi: 10.1002/pros.24300.
PubMed Abstract available

VLACHOSTERGIOS PJ, Niaz MJ, Thomas C, Christos PJ, et al
Pilot study of the diagnostic utility of (89) Zr-df-IAB2M and (68) Ga-PSMA-11 PET imaging and multiparametric MRI in localized prostate cancer.
Prostate. 2022 Jan 5. doi: 10.1002/pros.24294.
PubMed Abstract available

SEREF C, Acar O, Kilic M, Vural M, et al
Histologically benign PI-RADS 4 and 5 lesions contain cancer-associated epigenetic alterations.
Prostate. 2022;82:145-153.
PubMed Abstract available

YUAN W, Liu B, Sanda M, Wei R, et al
Glycoforms of human prostate-specific membrane antigen (PSMA) in human cells and prostate tissue.
Prostate. 2022;82:132-144.
PubMed Abstract available

WIDJAJA L, Derlin T, Ross TL, Bengel FM, et al
Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMA-targeted radioligand therapy.
Prostate. 2022;82:86-96.
PubMed Abstract available

December 2021

SNIPAITIENE K, Bakavicius A, Lazutka JR, Ulys A, et al
Urinary microRNAs can predict response to abiraterone acetate in castration resistant prostate cancer: A pilot study.
Prostate. 2021 Dec 30. doi: 10.1002/pros.24293.
PubMed Abstract available

MIKOSHI A, Miyai K, Hamabe F, Edo H, et al
MRI-detectability and histological factors of prostate cancer including intraductal carcinoma and cribriform pattern.
Prostate. 2021 Dec 28. doi: 10.1002/pros.24291.
PubMed Abstract available

SIENKIEWICZ K, Yang C, Paschal BM, Ratan A, et al
Genomic analyses of the metastasis-derived prostate cancer cell lines LNCaP, VCaP, and PC3-AR.
Prostate. 2021 Dec 24:e24290. doi: 10.1002/pros.24290.
PubMed Abstract available

HE H, Han D, Xu F, Lyu J, et al
How socioeconomic and clinical factors impact prostate-cancer-specific and other-cause mortality in prostate cancer stratified by clinical stage: Competing-risk analysis.
Prostate. 2021 Dec 20. doi: 10.1002/pros.24287.
PubMed Abstract available

URABE F, Miki K, Kimura T, Sasaki H, et al
Clinical significance of unfavorable findings in intermediate-risk prostate cancer patients for predicting treatment outcomes after contemporary, dose-escalated multimodal radiotherapy.
Prostate. 2021 Dec 16. doi: 10.1002/pros.24289.
PubMed Abstract available

KAUFMANN B, Saba K, Schmidli TS, Stutz S, et al
Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
Prostate. 2021 Dec 16. doi: 10.1002/pros.24286.
PubMed Abstract available

BARLOW SK, Oyekunle T, Janes JL, De Hoedt AM, et al
Prostate weight and prostate cancer outcomes after radical prostatectomy: Results from the SEARCH cohort study.
Prostate. 2021 Dec 14. doi: 10.1002/pros.24283.
PubMed Abstract available

LEFEBVRE F, Blanchet-Deverly A, Michineau L, Blanchet P, et al
Metabolic syndrome and prostate cancer in Afro-Caribbean men.
Prostate. 2021 Dec 14:e24281. doi: 10.1002/pros.24281.
PubMed Abstract available

POCKROS B, Stensland KD, Parries M, Frankenberger E, et al
Preoperative MRI PI-RADS scores are associated with prostate cancer upstaging on surgical pathology.
Prostate. 2021 Dec 8. doi: 10.1002/pros.24280.
PubMed Abstract available

ZAREI A, Javid H, Sanjarian S, Senemar S, et al
Metagenomics studies for the diagnosis and treatment of prostate cancer.
Prostate. 2021 Dec 2. doi: 10.1002/pros.24276.
PubMed Abstract available

MATTI B, Reeves F, Prouse M, Zargar-Shoshtari K, et al
The impact of the extent and location of positive surgical margins on the risk of biochemical recurrence following radical prostatectomy in men with Gleason 7 prostate cancers.
Prostate. 2021;81:1428-1434.
PubMed Abstract available

NAYAN M, Salari K, Bozzo A, Ganglberger W, et al
Predicting survival after radical prostatectomy: Variation of machine learning performance by race.
Prostate. 2021;81:1355-1364.
PubMed Abstract available

YAMOAH K, Asamoah FA, Abrahams AOD, Awasthi S, et al
Prostate tumors of native men from West Africa show biologically distinct pathways-A comparative genomic study.
Prostate. 2021;81:1402-1410.
PubMed Abstract available

TAKEZAWA K, Fujita K, Matsushita M, Motooka D, et al
The Firmicutes/Bacteroidetes ratio of the human gut microbiota is associated with prostate enlargement.
Prostate. 2021;81:1287-1293.
PubMed Abstract available

WENZEL M, Wurnschimmel C, Chierigo F, Tian Z, et al
Increased risk of postoperative in-hospital complications after radical prostatectomy in patients with prior organ transplant.
Prostate. 2021;81:1294-1302.
PubMed Abstract available

November 2021

NAKAYAMA H, Sekine Y, Oka D, Miyazawa Y, et al
Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
Prostate. 2021 Nov 29. doi: 10.1002/pros.24274.
PubMed Abstract available

VESTRIS PG, Gourtaud G, Senechal C, Sadreux Y, et al
Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC).
Prostate. 2021 Nov 25. doi: 10.1002/pros.24270.
PubMed Abstract available

PLAMBECK BD, Wang LL, Mcgirr S, Jiang J, et al
Effects of the 2012 and 2018 US preventive services task force prostate cancer screening guidelines on pathologic outcomes after prostatectomy.
Prostate. 2021 Nov 22. doi: 10.1002/pros.24261.
PubMed Abstract available

PREISSER F, Wurnschimmel C, Pose RM, Heinze A, et al
Concordance of biopsy and pathologic ISUP grading in salvage radical prostatectomy patients for recurrent prostate cancer.
Prostate. 2021 Nov 22. doi: 10.1002/pros.24268.
PubMed Abstract available

NAKAZAWA M, Fang M, H Marshall C, Lotan TL, et al
Clinical and genomic features of SPOP-mutant prostate cancer.
Prostate. 2021 Nov 15. doi: 10.1002/pros.24269.
PubMed Abstract available

TRYGGESTAD AMA, Axcrona K, Axcrona U, Bigalke I, et al
Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy.
Prostate. 2021 Nov 11. doi: 10.1002/pros.24267.
PubMed Abstract available

HANSKE J, Risse Y, Roghmann F, Pucheril D, et al
Comparison of prostate cancer detection rates in patients undergoing MRI/TRUS fusion prostate biopsy with two different software-based systems.
Prostate. 2021 Nov 3. doi: 10.1002/pros.24264.
PubMed Abstract available

MIYAHIRA AK, Zarif JC, Coombs CC, Flavell RR, et al
Prostate cancer research in the 21st century; report from the 2021 Coffey-Holden prostate cancer academy meeting.
Prostate. 2021 Nov 3. doi: 10.1002/pros.24262.
PubMed Abstract available

October 2021

SHI Z, Lu L, Resurreccion WK, Yang W, et al
Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: A meta-analysis.
Prostate. 2021 Oct 21. doi: 10.1002/pros.24252.
PubMed Abstract available

PILLING A, Kim SH, Hwang C
Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
Prostate. 2021 Oct 21. doi: 10.1002/pros.24257.
PubMed Abstract available

LUO LS, Jiang JF, Luan HH, Zi H, et al
Spatial and temporal patterns of prostate cancer burden and their association with Socio-Demographic Index in Asia, 1990-2019.
Prostate. 2021 Oct 18. doi: 10.1002/pros.24258.
PubMed Abstract available

KIM S, Li L, Zhang J, Jiang C, et al
Aqueous metabolome of tissue-specific conditional Pten-knockout mouse prostate cancer and TRAMP neuroendocrine carcinoma.
Prostate. 2021 Oct 18. doi: 10.1002/pros.24256.
PubMed Abstract available

HOEH B, Wurnschimmel C, Flammia RS, Horlemann B, et al
Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients.
Prostate. 2021 Oct 18. doi: 10.1002/pros.24253.
PubMed Abstract available

WENZEL M, Colla Ruvolo C, Wurnschimmel C, Nocera L, et al
Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients.
Prostate. 2021 Oct 11. doi: 10.1002/pros.24249.
PubMed Abstract available

IKEUCHI W, Wakita Y, Zhang G, Li C, et al
AT-rich interaction domain 5A regulates the transcription of interleukin-6 gene in prostate cancer cells.
Prostate. 2021 Oct 11. doi: 10.1002/pros.24251.
PubMed Abstract available

JIMBO M, Andrews JR, Ahmed ME, Dundar A, et al
Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy.
Prostate. 2021 Oct 11. doi: 10.1002/pros.24246.
PubMed Abstract available

PREBAY ZJ, Medairos R, Doolittle J, Langenstroer P, et al
The prognostic value of digital rectal exam for the existence of advanced pathologic features after prostatectomy.
Prostate. 2021;81:1064-1070.
PubMed Abstract available

September 2021

YIN Y, Liu Q, Shao Y, He X, et al
Regulatory mechanism of androgen receptor on NCAPD3 gene expression in prostate cancer.
Prostate. 2021 Sep 30. doi: 10.1002/pros.24245.
PubMed Abstract available

YU C, Niu L, Li L, Li T, et al
Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis.
Prostate. 2021 Sep 30. doi: 10.1002/pros.24229.
PubMed Abstract available

YANAGISAWA T, Kimura T, Mori K, Suzuki H, et al
Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
Prostate. 2021 Sep 24. doi: 10.1002/pros.24243.
PubMed Abstract available

YONEYAMA T, Yamamoto H, Sutoh Yoneyama M, Tobisawa Y, et al
Characteristics of alpha2,3-sialyl N-glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level.
Prostate. 2021 Sep 21. doi: 10.1002/pros.24239.
PubMed Abstract available

HERNANDEZ-LLODRA S, Segales L, Juanpere N, Marta Lorenzo T, et al
SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
Prostate. 2021 Sep 17. doi: 10.1002/pros.24218.
PubMed Abstract available

HOEH B, Wurnschimmel C, Flammia RS, Horlemann B, et al
Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients.
Prostate. 2021 Sep 15. doi: 10.1002/pros.24235.
PubMed Abstract available

JIMENEZ-ALCAIDE E, Garcia-Fuentes C, Hernandez V, De la Pena E, et al
Influence of androgen deprivation therapy on the severity of COVID-19 in prostate cancer patients.
Prostate. 2021 Sep 13. doi: 10.1002/pros.24232.
PubMed Abstract available

LETHONGSAVARN V, Pinault M, Diedhiou A, Guimaraes C, et al
Tissue cholesterol metabolism and prostate cancer aggressiveness: Ethno-geographic variations.
Prostate. 2021 Sep 13. doi: 10.1002/pros.24234.
PubMed Abstract available

AYDOS U, Cetin S, Akdemir UO, Budak FC, et al
The role of histopathological and biochemical parameters for predicting metastatic disease on (68) Ga-PSMA-11 PET in prostate cancer.
Prostate. 2021 Sep 13. doi: 10.1002/pros.24231.
PubMed Abstract available

WATANABE R, Maekawa M, Kiyoi T, Kurata M, et al
PSMA-positive membranes secreted from prostate cancer cells have potency to transform vascular endothelial cells into an angiogenic state.
Prostate. 2021 Sep 13. doi: 10.1002/pros.24237.
PubMed Abstract available

LIU Y, Dong Y, Liu J, Zhang X, et al
Comparison between (18) F-DCFPyL PET and MRI for the detection of transition zone prostate cancer.
Prostate. 2021 Sep 13. doi: 10.1002/pros.24230.
PubMed Abstract available

CHHATRE S, Malkowicz SB, Jayadevappa R
Continuity of care in acute survivorship phase, and short and long-term outcomes in prostate cancer patients.
Prostate. 2021 Sep 13. doi: 10.1002/pros.24228.
PubMed Abstract available

SOKOLOVA AO, Marshall CH, Lozano R, Gulati R, et al
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.
Prostate. 2021 Sep 13. doi: 10.1002/pros.24236.
PubMed Abstract available

CHO MC, Yoo S, Choo MS, Son H, et al
Lymphocyte-to-monocyte ratio is a predictor of clinically significant prostate cancer at prostate biopsy.
Prostate. 2021 Sep 13. doi: 10.1002/pros.24222.
PubMed Abstract available

MANGOSH TL, Grabowska MM, Taylor DJ
SLX4IP N-terminus dictates telomeric localization in ALT-like castration-resistant prostate cancer cell lines.
Prostate. 2021 Sep 7. doi: 10.1002/pros.24225.
PubMed Abstract available

MATSUDA T, Miyata Y, Nakamura Y, Otsubo A, et al
Pathological significance and prognostic role of LATS2 in prostate cancer.
Prostate. 2021 Sep 7. doi: 10.1002/pros.24226.
PubMed Abstract available

MIYAHIRA AK, Soule HR
The 27th Annual Prostate Cancer Foundation Scientific Retreat Report.
Prostate. 2021 Sep 1. doi: 10.1002/pros.24211.
PubMed Abstract available

SUMAN S, Parghane RV, Joshi A, Prabhash K, et al
Combined (177) Lu-PSMA-617 PRLT and abiraterone acetate versus (177) Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer: An observational study comparing the response and durability.
Prostate. 2021 Sep 1. doi: 10.1002/pros.24219.
PubMed Abstract available

EKSI M, Evren I, Akkas F, Arikan Y, et al
Machine learning algorithms can more efficiently predict biochemical recurrence after robot-assisted radical prostatectomy.
Prostate. 2021;81:913-920.
PubMed Abstract available

IAKYMENKO OA, Lugo I, Briski LM, Nemov I, et al
Percentage of Gleason pattern 4 and tumor volume predict adverse pathological stage and margin status at radical prostatectomy in grade Group 2 and grade Group 3 prostate cancers.
Prostate. 2021;81:866-873.
PubMed Abstract available

MARTINEZ O, Murphy C, Bsatee A, Abaza R, et al
Impact of median lobe on urinary function after robotic prostatectomy.
Prostate. 2021;81:832-837.
PubMed Abstract available

LONERGAN PE, Cowan JE, Washington SL 3rd, Greenberg SA, et al
Natural history of an immediately detectable PSA following radical prostatectomy in a contemporary cohort.
Prostate. 2021;81:1009-1017.
PubMed Abstract available

SANCHES BDA, Maldarine JS, Vilamaior PSL, Felisbino SL, et al
Stromal cell interplay in prostate development, physiology, and pathological conditions.
Prostate. 2021;81:926-937.
PubMed Abstract available

WEE CE, Costello BA, Orme JJ, Quevedo JF, et al
Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience.
Prostate. 2021;81:938-943.
PubMed Abstract available

August 2021

LEDET EM, Sartor O
Letter to the Editor: "Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients".
Prostate. 2021 Aug 31. doi: 10.1002/pros.24221.
PubMed

DI MAIDA F, Grosso AA, Minervini A
Letter to the Editor: "Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients".
Prostate. 2021 Aug 31. doi: 10.1002/pros.24220.
PubMed

SHAO L, Wang J, Karatas O, Ittmann M, et al
MEX3D is an oncogenic driver in prostate cancer.
Prostate. 2021 Aug 29. doi: 10.1002/pros.24216.
PubMed Abstract available

SUN BL
Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
Prostate. 2021 Aug 26. doi: 10.1002/pros.24213.
PubMed Abstract available

WANG Z, Zhu S, Zhao J, Nie L, et al
The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.
Prostate. 2021 Aug 26. doi: 10.1002/pros.24215.
PubMed Abstract available

OKINAKA Y, Kageyama S, Nishizawa K, Yoshida T, et al
Clinical, pathological, and therapeutic features of newly diagnosed prostate cancer predominantly detected by opportunistic PSA screening: A survey of Shiga Prefecture, Japan.
Prostate. 2021 Aug 21. doi: 10.1002/pros.24212.
PubMed Abstract available

HAFFNER MC, Bhamidipati A, Tsai HK, Esopi DM, et al
Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer.
Prostate. 2021 Aug 16. doi: 10.1002/pros.24210.
PubMed Abstract available

WENZEL M, Wurnschimmel C, Nocera L, Ruvolo CC, et al
The effect of primary urological cancers on survival in men with secondary prostate cancer.
Prostate. 2021 Aug 16. doi: 10.1002/pros.24209.
PubMed Abstract available

NANDALUR KR, Colvin R, Walker D, Nandalur SR, et al
Benign prostate hyperplasia as a potential protective factor against prostate cancer: Insights from a magnetic resonance imaging study of compositional characteristics.
Prostate. 2021 Aug 10. doi: 10.1002/pros.24207.
PubMed Abstract available

WURNSCHIMMEL C, Wenzel M, Wang N, Tian Z, et al
Long-term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life-table data.
Prostate. 2021;81:785-793.
PubMed Abstract available

WURNSCHIMMEL C, Wenzel M, Chierigo F, Flammia RS, et al
Presence of biopsy Gleason pattern 5 + 3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patterns.
Prostate. 2021;81:778-784.
PubMed Abstract available

WAGASKAR VG, Ratnani P, Levy M, Moody K, et al
Clinical characteristics and oncological outcomes in negative multiparametric MRI patients undergoing robot-assisted radical prostatectomy.
Prostate. 2021;81:772-777.
PubMed Abstract available

July 2021

ROSSIGNOL T, Gourtaud G, Senechal C, Sadreux Y, et al
Characteristics and progression-free survival of Afro-Caribbean men with metastatic hormone-sensitive prostate cancer at the time of diagnosis.
Prostate. 2021 Jul 28. doi: 10.1002/pros.24206.
PubMed Abstract available

LEIS-FILHO AF, Lainetti PD, Kobayashi PE, Palmieri C, et al
Expression and prognostic significance of vascular endothelial growth factor-A (VEGF-A) and its receptor in canine prostate cancer.
Prostate. 2021 Jul 28. doi: 10.1002/pros.24199.
PubMed Abstract available

CAO Y, Zhang W, Li Y, Fu J, et al
Rates and trends in stage-specific prostate cancer incidence by age and race/ethnicity, 2000-2017.
Prostate. 2021 Jul 28. doi: 10.1002/pros.24204.
PubMed Abstract available

WENZEL M, Wurnschimmel C, Chierigo F, Tian Z, et al
Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients.
Prostate. 2021 Jul 26. doi: 10.1002/pros.24202.
PubMed Abstract available

CHAO OS, Goodman OB Jr
DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
Prostate. 2021 Jul 23. doi: 10.1002/pros.24200.
PubMed Abstract available

EPSTEIN JI
Very low-risk versus low-risk prostate cancer: A distinction worth keeping.
Prostate. 2021 Jul 12. doi: 10.1002/pros.24197.
PubMed

WEI J, Yang W, Shi Z, Lu L, et al
Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort.
Prostate. 2021 Jul 12. doi: 10.1002/pros.24195.
PubMed Abstract available

FETTKE H, Kwan EM, Bukczynska P, Steen JA, et al
Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer.
Prostate. 2021 Jul 12. doi: 10.1002/pros.24194.
PubMed Abstract available

LIU G, Zhu Y, Yao Z, Jiang Y, et al
Development and validation of a predictive model for determining clinically significant prostate cancer in men with negative magnetic resonance imaging after transrectal ultrasound-guided prostate biopsy.
Prostate. 2021 Jul 12. doi: 10.1002/pros.24193.
PubMed Abstract available

HUANG D, Ruan X, Wu Y, Lin X, et al
Genetic polymorphisms at 19q13.33 are associated with [-2]proPSA (p2PSA) levels and provide additional predictive value to prostate health index for prostate cancer.
Prostate. 2021 Jul 12. doi: 10.1002/pros.24192.
PubMed Abstract available

LAUNER BM, Lloyd GL
Sociodemographic index and global trends in prostate cancer: 1990-2017.
Prostate. 2021 Jul 5. doi: 10.1002/pros.24178.
PubMed Abstract available

CHEN DY, Su PJ, See LC, Liu JR, et al
Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study.
Prostate. 2021 Jul 1. doi: 10.1002/pros.24187.
PubMed Abstract available

BROGGI G, Lo Giudice A, Di Mauro M, Asmundo MG, et al
SRSF-1 and microvessel density immunohistochemical analysis by semi-automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study).
Prostate. 2021 Jul 1. doi: 10.1002/pros.24185.
PubMed Abstract available

CORRADI JP, Cumarasamy CW, Staff I, Tortora J, et al
Identification of a five gene signature to predict time to biochemical recurrence after radical prostatectomy.
Prostate. 2021;81:694-702.
PubMed Abstract available

June 2021

LV S, Pu X, Luo M, Wen H, et al
Long noncoding RNA GAS5 interacts and suppresses androgen receptor activity in prostate cancer cells.
Prostate. 2021 Jun 29. doi: 10.1002/pros.24186.
PubMed Abstract available

WENZEL M, Wurnschimmel C, Ruvolo CC, Nocera L, et al
Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores.
Prostate. 2021 Jun 29. doi: 10.1002/pros.24184.
PubMed Abstract available

LENDINEZ-CANO G, Ojeda-Claro AV, Gomez-Gomez E, Morales Jimenez P, et al
Prospective study of diagnostic accuracy in the detection of high-grade prostate cancer in biopsy-naive patients with clinical suspicion of prostate cancer who underwent the Select MDx test.
Prostate. 2021 Jun 29. doi: 10.1002/pros.24182.
PubMed Abstract available

BASU HS, Wilganowski N, Robertson S, Reuben JM, et al
Prostate cancer cells survive anti-androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities.
Prostate. 2021 Jun 25. doi: 10.1002/pros.24146.
PubMed Abstract available

NUNES-XAVIER CE, Kildal W, Kleppe A, Danielsen HE, et al
Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer.
Prostate. 2021 Jun 14. doi: 10.1002/pros.24180.
PubMed Abstract available

WURNSCHIMMEL C, Kachanov M, Wenzel M, Mandel P, et al
Twenty-year trends in prostate cancer stage and grade migration in a large contemporary german radical prostatectomy cohort.
Prostate. 2021 Jun 10. doi: 10.1002/pros.24181.
PubMed Abstract available

FALEGAN OS, Jarvi K, Vogel HJ, Hyndman ME, et al
Seminal plasma metabolomics reveals lysine and serine dysregulation as unique features distinguishing between prostate cancer tumors of Gleason grades 6 and 7.
Prostate. 2021 Jun 7. doi: 10.1002/pros.24145.
PubMed Abstract available

WANG L, Li H, Li Z, Li M, et al
Smoothened loss is a characteristic of neuroendocrine prostate cancer.
Prostate. 2021;81:508-520.
PubMed Abstract available

NIZIALEK E, Lim SJ, Wang H, Isaacsson Velho P, et al
Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.
Prostate. 2021;81:572-579.
PubMed Abstract available

WESTHOFEN T, Buchner A, Schlenker B, Becker A, et al
A matter of size? Health-related quality of life after radical prostatectomy for patients with giant prostates.
Prostate. 2021;81:443-451.
PubMed Abstract available

CIPOLLARI S, Jamshidi N, Du L, Sung K, et al
Tissue clearing techniques for three-dimensional optical imaging of intact human prostate and correlations with multi-parametric MRI.
Prostate. 2021;81:521-529.
PubMed Abstract available

XIAO GQ, Ho G, Suen C, Hurth KM, et al
Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma.
Prostate. 2021;81:469-477.
PubMed Abstract available

May 2021

LOEB S, Li R, Sanchez Nolasco T, Byrne N, et al
Barriers and facilitators of germline genetic evaluation for prostate cancer.
Prostate. 2021 May 31. doi: 10.1002/pros.24172.
PubMed Abstract available

QUHAL F, Rajwa P, Mori K, Laukhtina E, et al
The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer.
Prostate. 2021 May 31. doi: 10.1002/pros.24173.
PubMed Abstract available

SI S, Zheng B, Wang Z, Niu Z, et al
Does surgery benefit patients with oligometastatic or metastatic prostate cancer? - A retrospective cohort study and meta-analysis.
Prostate. 2021 May 31. doi: 10.1002/pros.24170.
PubMed Abstract available

MISHRA A, Zennami K, Velarde E, Thorek DLJ, et al
Longitudinal measurement of subcutaneous and intratibial human prostate cancer xenograft growth and response to ionizing radiation by plasma Alu and LINE-1 ctDNA: A comparison to standard methods.
Prostate. 2021 May 25. doi: 10.1002/pros.24171.
PubMed Abstract available

ZHU S, Chen J, Ni Y, Zhang H, et al
Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patients.
Prostate. 2021 May 24. doi: 10.1002/pros.24167.
PubMed Abstract available

WENZEL M, Wurnschimmel C, Chierigo F, Tian Z, et al
Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy.
Prostate. 2021 May 19. doi: 10.1002/pros.24169.
PubMed Abstract available

FERRARIS F, Yaber F, Smith AB, Barreiro D, et al
The end of "very low risk" in localized prostate cancer?
Prostate. 2021 May 19. doi: 10.1002/pros.24168.
PubMed

SARTOR O, Appukkuttan S, Weiss J, Tsao CK, et al
Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settings.
Prostate. 2021 May 12. doi: 10.1002/pros.24143.
PubMed Abstract available

XU J, Isaacs WB, Mamawala M, Shi Z, et al
Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients.
Prostate. 2021 May 6. doi: 10.1002/pros.24140.
PubMed Abstract available

BANERJEE M, Li Z, Gao Y, Lai F, et al
Inverse agonism at the Na/K-ATPase receptor reverses EMT in prostate cancer cells.
Prostate. 2021 May 6. doi: 10.1002/pros.24144.
PubMed Abstract available

WANG V, Geybels MS, Jordahl KM, Gerke T, et al
A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.
Prostate. 2021 May 6. doi: 10.1002/pros.24148.
PubMed Abstract available

DE GROOT AE, Myers KV, Krueger TEG, Kiemen AL, et al
Characterization of tumor-associated macrophages in prostate cancer transgenic mouse models.
Prostate. 2021 May 5. doi: 10.1002/pros.24139.
PubMed Abstract available

CHI JT, Lin PH, Tolstikov V, Oyekunle T, et al
The influence of low-carbohydrate diets on the metabolic response to androgen-deprivation therapy in prostate cancer.
Prostate. 2021 May 5. doi: 10.1002/pros.24136.
PubMed Abstract available

ONAL C, Ozyigit G, Oymak E, Guler OC, et al
Clinical parameters and nomograms for predicting lymph node metastasis detected with (68) Ga-PSMA-PET/CT in prostate cancer patients candidate to definitive radiotherapy.
Prostate. 2021 May 5. doi: 10.1002/pros.24142.
PubMed Abstract available

WENZEL M, Wurnschimmel C, Nocera L, Colla Ruvolo C, et al
The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients.
Prostate. 2021;81:339-346.
PubMed Abstract available

LEON P, Cancel-Tassin G, Bourdon V, Buecher B, et al
Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer.
Prostate. 2021;81:318-325.
PubMed Abstract available

ZHAO H, Howard LE, De Hoedt AM, Terris MK, et al
Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population.
Prostate. 2021;81:390-397.
PubMed Abstract available

April 2021

TAN B, Chen X, Fan Y, Yang Y, et al
STAT3 phosphorylation is required for the HepaCAM-mediated inhibition of castration-resistant prostate cancer cell viability and metastasis.
Prostate. 2021 Apr 28. doi: 10.1002/pros.24141.
PubMed Abstract available

BALLAL S, Yadav MP, Sahoo RK, Tripathi M, et al
(225) Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
Prostate. 2021 Apr 27. doi: 10.1002/pros.24137.
PubMed Abstract available

QU F, Gu Y, Xue M, He M, et al
Impact of therapy on cancer metabolism in high-risk localized prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.
Prostate. 2021 Apr 27. doi: 10.1002/pros.24134.
PubMed Abstract available

HISHIDA S, Kawakami K, Fujita Y, Kato T, et al
Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer.
Prostate. 2021 Apr 27. doi: 10.1002/pros.24138.
PubMed Abstract available

BOSLAND MC, Nettey OS, Phillips AA, Anunobi CC, et al
Prevalence of prostate cancer at autopsy in Nigeria-A preliminary report.
Prostate. 2021 Apr 27. doi: 10.1002/pros.24133.
PubMed Abstract available

ONAL C, Kose F, Ozyigit G, Aksoy S, et al
Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
Prostate. 2021 Apr 27. doi: 10.1002/pros.24132.
PubMed Abstract available

BAZZI LA, Sigurdardottir LG, Sigurdsson S, Valdimarsdottir U, et al
Exploratory assessment of pineal gland volume, composition, and urinary 6-sulfatoxymelatonin levels on prostate cancer risk.
Prostate. 2021 Apr 16. doi: 10.1002/pros.24130.
PubMed Abstract available

THULIN MH, Maatta J, Linder A, Sterbova S, et al
Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
Prostate. 2021 Apr 6. doi: 10.1002/pros.24125.
PubMed Abstract available

WANG Y, Wu G, Fan L, Pan J, et al
The prognostic nomogram including MRI for locally advanced prostate cancer treated by radical prostatectomy.
Prostate. 2021 Apr 6. doi: 10.1002/pros.24126.
PubMed Abstract available

March 2021

SWANSON GP, Lenz L, Stone S, Cohen T, et al
Cell-cycle risk score more accurately determines the risk for metastases and death in prostatectomy patients compared with clinical features alone.
Prostate. 2021;81:261-267.
PubMed Abstract available

TAN YG, Khalid F, Huang HH, Chen K, et al
Prostatic ductal adenocarcinoma variant predicts worse pathological and oncological outcomes: Insight from over 1000 consecutive patients from a large prospective uro-oncology registry.
Prostate. 2021;81:242-251.
PubMed Abstract available

LI Y, Ge C, Franceschi RT
Role of Runx2 in prostate development and stem cell function.
Prostate. 2021;81:231-241.
PubMed Abstract available

February 2021

LEE JM, Kim U, Yang H, Ryu B, et al
TALEN-mediated generation of Nkx3.1 knockout rat model.
Prostate. 2021;81:182-193.
PubMed Abstract available

January 2021

ZHU Y, Wen J, Huang G, Mittlesteadt J, et al
CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
Prostate. 2021;81:81-88.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: